HEMATOLOGIC MALIGNANCIES

This study tests a stem cell transplant for children and young adults with blood cancers like leukemia. Donor cells are specially treated to remove certain immune cells, which may lower the risk of serious side effects. The goal is to see if this approach helps the new cells grow…

This study tests a special type of donor cell infusion (called TCRαβ+/CD19+ depleted DLI) given after a stem cell transplant to help control high-risk blood cancers like leukemia. The goal is to find a safe dose and see if it reduces side effects like graft-versus-host disease. A…

This program gives patients with certain blood cancers access to Orca-T, a cell therapy, only when their prescribed commercial version is out of specification or expired. The goal is to provide treatment when no other option is available, but it is not a cure and requires ongoing…

This study tests a new way to choose cord blood for transplant in people with blood cancers like leukemia or lymphoma. Patients receive a cord blood transplant plus stem cells from a family member. The goal is to find the lowest safe cord blood dose that still leads to successful…

This early-phase study tests a new drug called KQB198, alone or with other cancer drugs, in adults with advanced blood cancers (like certain leukemias). The main goals are to find a safe dose and see if it shrinks tumors. About 13 participants will take the drug daily and have fr…

This early-stage study tests a new drug called GNC-035 in 33 adults with blood cancers that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose. The drug is a special antibody designed to attack cancer cells in multiple ways…

This study tests a new drug called teclistamab in about 40 Japanese patients whose multiple myeloma has come back or stopped responding to other treatments. The drug is a special antibody that helps the immune system attack cancer cells. The goal is to see if it is safe and how w…

This study follows up to 500 children and young adults who have already received gene therapy for cancer as part of an earlier trial. The goal is to monitor for any delayed side effects over the next 15 years. Participants will have regular blood tests and health check-ups, but n…

This study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma, leukemia, or multiple myeloma. The goal is to watch for long-term side effects, as required by regulators. Participants wi…